Gabelli Funds
CGTX icon

Gabelli Funds’s Cognition Therapeutics CGTX Stock Holding History

Gabelli Funds’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$28.8K Hold
30,000
– – ﹤0.01% 1238
2026
Q2 		$34.5K Hold
30,000
– – ﹤0.01% 1248
2026
Q1 		$22.8K Buy
+30,000
New +$34.9K ﹤0.01% 1239

Other funds holding CGTX

BIOS Capital Management
BIOS Capital Management Fort Worth, Texas $34.2M AUM 13.29% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.38B AUM 21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Hilton Capital Management
Hilton Capital Management Garden City, New York $1.47B AUM 11.48% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
CM
CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return

Gabelli Funds's CGTX Position: Q3 2026 in Review

Gabelli Funds held its Cognition Therapeutics (CGTX) position steady in Q3 2026 at 30,000 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1238.

Gabelli Funds first reported a position in CGTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $34.5K in Q2 2026. 60 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.

  • Gabelli Funds held 30,000 shares of Cognition Therapeutics worth $28.8K as of Q3 2026.
  • Gabelli Funds left its Cognition Therapeutics share count unchanged in Q3 2026.
  • Cognition Therapeutics made up ﹤0.01% of Gabelli Funds's portfolio in Q3 2026, its #1238 holding.
  • Gabelli Funds first reported a position in Cognition Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Gabelli Funds's Cognition Therapeutics position peaked at $34.5K in Q2 2026.
  • 60 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.

Based on Gabelli Funds's 13F filing for Q3 2026, filed 12 Nov 2026.